Switch theme
Sign up to access all valuation multiples
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
2015
19
LTM Revenue $13K
LTM EBITDA n/a
$31.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medicenna Therapeutics has a last 12-month revenue of $13K and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Medicenna Therapeutics achieved revenue of n/a and an EBITDA of -$13.1M.
Medicenna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medicenna Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$11.4M | -$13.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$15.8M | -$7.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medicenna Therapeutics's stock price is CAD 1 (or $1).
Medicenna Therapeutics has current market cap of CAD 74.3M (or $52.0M), and EV of CAD 44.5M (or $31.1M).
See Medicenna Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31.1M | $52.0M | XXX | XXX | XXX | XXX | $-0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medicenna Therapeutics has market cap of $52.0M and EV of $31.1M.
Medicenna Therapeutics's trades at 2471.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Medicenna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medicenna Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $31.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -3.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedicenna Therapeutics's NTM/LTM revenue growth is 3489%
Medicenna Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Medicenna Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medicenna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medicenna Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medicenna Therapeutics acquired XXX companies to date.
Last acquisition by Medicenna Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Medicenna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medicenna Therapeutics founded? | Medicenna Therapeutics was founded in 2015. |
| Where is Medicenna Therapeutics headquartered? | Medicenna Therapeutics is headquartered in Canada. |
| How many employees does Medicenna Therapeutics have? | As of today, Medicenna Therapeutics has 19 employees. |
| Who is the CEO of Medicenna Therapeutics? | Medicenna Therapeutics's CEO is Dr. Fahar Merchant,PhD. |
| Is Medicenna Therapeutics publicy listed? | Yes, Medicenna Therapeutics is a public company listed on TSE. |
| What is the stock symbol of Medicenna Therapeutics? | Medicenna Therapeutics trades under MDNA ticker. |
| When did Medicenna Therapeutics go public? | Medicenna Therapeutics went public in 2015. |
| Who are competitors of Medicenna Therapeutics? | Similar companies to Medicenna Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Medicenna Therapeutics? | Medicenna Therapeutics's current market cap is $52.0M |
| What is the current revenue of Medicenna Therapeutics? | Medicenna Therapeutics's last 12-month revenue is $13K. |
| What is the current EV/Revenue multiple of Medicenna Therapeutics? | Current revenue multiple of Medicenna Therapeutics is 2471.3x. |
| Is Medicenna Therapeutics profitable? | Yes, Medicenna Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
